All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Novel Nephrology Drugs in Discovery in UNITED STATES

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Novome Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer

Contact the Supplier

Lead Product(s): Undisclosed

Therapeutic Area: Nephrology

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: DCVC Bio

Deal Size: $33.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 07, 2020

Details:

The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.